Table 1 Main characteristics of included studies
First author (publication year) | Country | Sample size (Intervention/Control) Sex | Target Population | Mean Age (Intervention/Control) | Mean BMI (Intervention/Control) | RCT design (Blinding) | Duration (weeks) | Form and dose of intervention | Comparison | Results |
|---|---|---|---|---|---|---|---|---|---|---|
Karvonen et al. 2002 [10] | Finland | 68 (23/45) Male and female | Hypercholesterolemic subjects | NR (28 to 65 years) | NR | Parallel (Double) | 6 Weeks | Camelina oil 30 g/d | Canola oil 30 g/d or olive oil | Camelina oil consumption did not significantly change in lipid profile comparison with placebo use. |
Schwab et al. 2018 [12] | Finland | 43 (23/21) Male and female | Volunteers with impaired fasting glucose | 58.9 ± 6.5 | 29.2 ± 2.4 | Parallel (Double) | 12 Weeks | Camelina oil 10 g/d | Limited intakes of fish and source of alpha-linolenic acid | Camelina oil consumption did not significantly change in glucose metabolism parameters comparison with placebo use. |
Musazadeh et al. 2021 [7] | Iran | 130 (63/67) Male and female | NAFLD patients | 44.30 ± 4.38/ 43.86 ± 6.07 | 34.19 ± 3.55/ 33.90 ± 2.65 | Parallel (Triple) | 12 Weeks | Camelina oil 20 g/d | Sunflower oil 20 g/d | Camelina oil consumption causes significant changes in lipid profile (except HDL-c) among NAFLD patients |
Dobrzyńska et al. 2021 [9] | Poland | 60 (30/30) Female | Postmenopausal women with dyslipidaemia | 55 ± 5/ 57 ± 4 | 26.7 ± 5.3/ 26.9 ± 6.4 | Parallel (Double) | 6 Weeks | Camelina oil 30 g/d | Canola oil 30 g/d | Camelina oil consumption did not change in lipid profile, anthropometric parameters and blood pressure comparison with placebo use. |
Lankinen et al. 2021 [11] | Finland | 46 (23/23) Male | Healthy men | 66.6 ± 5.6/ 64.8 ± 5.6 | 24.6 ± 2.6/ 24.8 ± 2.6 | Parallel (None) | 8 Weeks | Camelina oil 50 ml/d | Sunflower oil 50 ml/d | Camelina oil consumption did not significantly change in FBS comparison with placebo use. |
Musazadeh et al. 2022 [6] | Iran | 130 (63/67) Male and female | NAFLD patients | 44.30 ± 4.38/ 43.86 ± 6.07 | 34.19 ± 3.55/ 33.90 ± 2.65 | Parallel (Triple) | 12 Weeks | Camelina oil 20 g/d | Sunflower oil 20 g/d | Camelina oil intake led to a significant decrease in FI, and HOMA-IR in compared with the placebo group. |
Bellien et al. 2022 [8] | France | 81 (40/41) Male and female | Hypertensive patients with metabolic syndrome | 57.7 ± 8.4/ 55.0 ± 7.5 | 30.0 ± 4.0/ 30.3 ± 4.2 | Parallel (Double) | 24 Weeks | Camelina oil 5.2 g/d | A mixture of cyclodextrin | Compared with placebo, camelina oil increased fasting glycemia and HOMA-IR index, without affecting plasma lipids |